Quad Technologies Patents Novel T-Cell Activation Reagent for Car-T Cell ManufacturingBusiness Wire (press release)WOBURN, Mass.–(BUSINESS WIRE)–Quad Technologies, a leader in cell and gene therapy bioprocessing reagents, announced today the U.S. Pat… Continue reading
Mesothelioma & Asbestos Awareness Center (blog)The Potential of Immunotherapy with Chemotherapy or Radiation for MesotheliomaMesothelioma & Asbestos Awareness Center (blog)Chemotherapy, surgery and radiation have been the standard tools for treating al… Continue reading
Mesothelioma & Asbestos Awareness Center (blog)The Potential of Immunotherapy with Chemotherapy or Radiation for MesotheliomaMesothelioma & Asbestos Awareness Center (blog)Chemotherapy, surgery and radiation have been the standard tools for treating al… Continue reading
BioPharma-Reporter.com |
FDA panel recommends Luxturna gene therapy
AOP Diopsys advert A gene therapy for the treatment of the inherited eye disease, Leber congenital amaurosis (LCA), is a step closer to approval by the US Food and Drug Administration (FDA). The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee … ‘Luxturna’ recommendation good for all AAV based gene therapies says advocacy groupBioPharma-Reporter.com |
BioPharma-Reporter.com |
FDA panel recommends Luxturna gene therapy
AOP Diopsys advert A gene therapy for the treatment of the inherited eye disease, Leber congenital amaurosis (LCA), is a step closer to approval by the US Food and Drug Administration (FDA). The FDA’s Cellular, Tissue and Gene Therapies Advisory Committee … ‘Luxturna’ recommendation good for all AAV based gene therapies says advocacy groupBioPharma-Reporter.com |